Preclinical Study of SLS-004, Potential Parkinson’s Gene Therapy, Starting

Preclinical Study of SLS-004, Potential Parkinson’s Gene Therapy, Starting
Seelos Therapeutics announced it is beginning, earlier than expected, a preclinical study into its investigational gene therapy candidate for Parkinson’s disease called SLS-004. The exact nature of this early research work was not detailed in a press release. Nerve cell damage in Parkinson’s is caused by the buildup of toxic forms of the alpha-synuclein protein, and resulting clumps of misfolded proteins known as Lewy bodies. ... read more
Source: Parkinson’s News TodayPublished on 2020-06-01By Patricia Inacio, PhD